Market Access Blogs

03|23|23

Checking in with Patrick Beers

“Boomerangs” are employees who leave and then return, and there are a variety of reasons to bring someone back. Find out what made Patrick Beers, Senior Vice President, Market Access, venture back to EVERSANA INTOUCH and what he’s most excited about in this next chapter! 

09|28|21

Meet Intouch Market Access – Our Latest Full-Service Affiliate

Gaining access to the medications they need has long been an obstacle for patients. Find out more about how Intouch Market Access can help brands create life-changing opportunities for those who need them.

08|05|21

Trans Healthcare: How Pharma Marketers Can Positively Impact This Underserved Community

In this POV, you’ll learn about the hurdles transgender people face in seeking care, and how pharma marketers can help clear the path.

07|27|21

Drug Pricing Reform: Never Out of the Headlines

Drug pricing is not going to disappear from legislators’ desks, and even big-business-friendly politicians have pharma in their sights. Learn more about what pharma marketers need to know and do in this climate.

05|13|21

$ to Switch: What Brands Need to Know and Do About New PBM Tactics

If Cigna’s cash incentive becomes precedent, are you prepared to quickly react if your brand is the focus for a new non-medical switching campaign?

04|27|21

Drug Pricing Reform: Who Will Hold the Medicare Part D Contracting Cards?

Now is the time to scenario-plan for a world where drug pricing assumptions account for increased discounts. Find out what pharma needs to do to prepare for this evolution.

04|20|21

Three Areas Payers Are Redefining Following COVID-19

Intouch SVP of market access Mike Motto weighs in on how, in addition to value and technology, new payer partnerships and acquisitions are influencing this evolution.

02|04|21

Brand & Market Access Leaders, Your Time Is Now

New administration, new approach to healthcare: the old playbook isn’t enough anymore. Is your pharma brand ready to optimize patient, caregiver, and HCP experiences in this evolving landscape?

01|28|21

Concierge Medicine: The Good, the Bad, and the Ugly

How does concierge medicine affect patients, healthcare providers, and pharma? And what’s pharma’s role in this growing healthcare arena? Read on to find out.

08|19|20

Drug Pricing – How Pharma Can Ease the Burden

In this POV, market access gurus Mike Motto, Glen Davis, and Peter Weissberg, discuss recent Trump administration action on drug pricing, the likelihood of further action before the 2020 election, and how pharma manufacturers can provide affordable options for more Americans.